Replies to post #693611 on NorthWest Biotherapeutics Inc (NWBO)

[newman2021]

you better read the Nature paper putting oil in your eyes. It is upto Merck if they want to come to us to run the Keytruda combo trial in phase 3 giving us a lot of money. Their keytruda patent expires in a year or two. They better stop playing hardball.

[georgebailey]

Hope- the only 5 year survivors was on the vaccine only
My reading was the Nature publication highlighted how Poly super charged L.
Further, the long tail 9+ year survivors(4 of them) were mostly, if not all, grade 3 Glioma patients that got the combo.

#dcvax $nwbo #GBM

Al Musella:

"This is a very important publication. It shows that combining a personalized dendritic cell vaccine with an immune-boosting adjuvant can improve treatment efficacy. This Phase 2 study specifically looked at two different immune modulators -… pic.twitter.com/RbMIjHIylg

— Peter Davis (@peter_brit) May 14, 2024